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Carbon monoxide (CO) poisoning is typically treated by administration of oxygen via non-rebreather 
mask (NRB). High-flow nasal cannula (HFNC) is an alternative to NRB in a variety of disease states. 
We report a case of the novel use of HFNC in the treatment of acute CO poisoning. A 29-year-old 
man presented with a carboxyhemoglobin (COHb) level of 29.8%. He was treated with HFNC, 
and COHb levels declined to 5.4% in 230 minutes. Given several theoretical advantages of HFNC 
relative to NRB, HFNC is a potential option for use in the treatment of CO poisoning. [Clin Pract 
Cases Emerg Med. 2020;4(1):X–X.]   
INTRODUCTION
Carbon monoxide (CO) poisoning is a significant cause 
of morbidity and mortality causing approximately 500 deaths 
annually, and as many as 25,000 hospitalizations per year.1,2 The 
treatment of CO poisoning is primarily aimed at removing CO 
through competitive binding of hemoglobin by administration 
of supplemental oxygen. In the majority of cases this is done 
using a non-rebreather mask (NRB). Alternatively, hyperbaric 
oxygen may be used in cases of more severe toxicity based on 
very high levels of carboxyhemoglobin (COHb) or signs or 
symptoms of severe toxicity.
Delivery of supplemental oxygen via high-flow nasal 
cannula (HFNC) has been used with increasing frequency. 
HFNC allows for delivery of a higher flow rate of oxygen 
as well as positive pressure and administration of warmed, 
humidified oxygen. Proponents suggest that it can be 
advantageous over other forms of supplemental oxygen 
delivery as it is often better tolerated than a NRB, can provide 
some degree of positive pressure, is useful in washing out 
anatomic dead space, and allows for up to 60 liters per minute 
(LPM) of oxygen administration.3 High flow rate of oxygen 
reduces the dilution of inspired oxygen that occurs when the 
volume of inspired gas exceeds the flow rate of the NRB. 
As such, HFNC provides some theoretical advantages over 
NRB for the treatment of CO poisoning. To date we find two 
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recent reports of HFNC used to treat CO poisoning; however, 
widespread use has not been reported.4,5 Our case is submitted 
to support recent earlier findings and therefore support the 
novel use of HFNC following CO poisoning.
CASE REPORT
A 29-year-old man presented to the emergency department 
(ED) after being found in an idling car parked in an enclosed 
space. The patient had last been seen approximately four 
hours prior to being found in the car. He was awake and alert 
upon arrival. He had significant nausea but no vomiting.  He 
denied loss of consciousness, confusion, seizure, chest pain, 
shortness of breath or headache, or any concomitant ingestion. 
He had no significant medical or surgical history other than 
depression, but reported being a pack per day smoker. The 
patient had been transported from home via ambulance and 
administered 100% oxygen via NRB at a flow rate of 15 LPM 
for approximately 15 minutes during transport.  
On arrival, the patient’s blood pressure was 130/63 
millimeters of mercury (mmHg), pulse rate was 73 beats per 
minute, respiratory rate was 18 breaths per minute, oxygen 
saturation (SaO2) was 99% on NRB, and temperature 
was 36.6 degrees Celsius. He was awake and had normal 
mentation, and was in no apparent distress. Cardiovascular 
exam showed normal heart sounds, normal rhythm, no 
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What do we already know about this clinical 
entity? 
Carbon monoxide (CO) poisoning is 
effectively treated with supplemental oxygen, 
typically via a non-rebreather mask (NRB).  
In some clinical situations, however, patients 
may have difficulty tolerating the NRB. 
What makes this presentation of disease 
reportable? 
There are no prior reports of the use of high 
flow nasal cannula (HFNC) in the literature 
outside those reported using a strict study 
protocol. Our report supports effectiveness in 
clinical practice.
What is the major learning point? 
HFNC is a likely effective option for the 
administration of supplemental oxygen when 
treating CO poisoning.
How might this improve emergency medicine 
practice? 
Our report supports the use of HFNC which 
has distinct advantages over use of a NRB 
when administering supplemental oxygen to 
patients with elevated CO levels.
murmurs, rubs or gallops. Respiratory exam revealed no 
respiratory distress, equal and clear breath sounds bilaterally. 
Neurologically, he was oriented to name, place, time, and 
purpose. He had normal speech, Glasgow Coma Scale of 15, 
normal memory, cranial nerves II-XII, and motor and sensory 
exams were completely normal. His gait was normal. He had no 
nystagmus. His psychiatric exam revealed that he was feeling 
suicidal. Otherwise, he had an unremarkable physical exam. 
Initial arterial blood gas (ABG) on room air shortly after 
arrival revealed a pH 7.369 [7.35-7.45], partial pressure of 
carbon dioxide (pCO
2
) of 41.9 mmHg (35-45 mmHg), partial 
pressure of oxygen (pO
2
) of 93.3 mmHg (75-100 mmHg), 
and COHb level of 29.8% (0-2%).  His electrocardiogram, 
serum electrolytes, liver function tests, creatinine kinase, and 
complete blood count were within normal range, excepting a 
potassium level of 3.1 milliequivalents per liter (mEq/L) (3.5-
5.1 mEq/L). Salicylate, troponin I, ethanol, and acetaminophen 
levels were below the assay limits of detection. 
Immediately after obtaining the ABG results the patient was 
started on 100% oxygen via HFNC at 30 LPM due to concerns 
that he would not tolerate the NRB and could vomit due to 
complaints of severe nausea. His nausea resolved within the 
first hour of HFNC treatment. After 112 minutes of therapy via 
HFNC, a repeat ABG revealed the following: pH 7.403, COHb 
11.5%, pCO
2
 42.1 mmHg, and pO
2
 of 462.4 mmHg. It was felt 
that the patient was responding to HFNC therapy as evidenced 
by the decline in COHb and the increase in pO
2
. HFNC therapy 
at the same settings was continued for a total of approximately 
230 minutes when a repeat ABG was obtained revealing a COHb 
of 5.4%. At this point the patient was asymptomatic and therapy 
was discontinued. Of note the patient did not receive antiemetic 
medication. Following administration of supplemental oral 
potassium he was transferred to the psychiatric service.
DISCUSSION
HFNC is a promising treatment option for hypoxic 
respiratory failure in the ED due to the ability to more 
comfortably deliver oxygen at a high rate as well as deliver 
positive pressure and wash out anatomic dead space. HFNC 
delivers warmed, humidified oxygen at flow rates of up to 60 
LMP and with positive pressure of 2-5 mmHg.6-9 The ability 
to warm the oxygen to core temperature and humidify at high 
flow rates also helps remove airway secretions, decreases 
work of breathing, and avoids drying out the airway, reducing 
epithelial injury.10 Current indications for HFNC in children 
include use for premature infants with respiratory distress 
syndrome and infants with bronchiolitis.11 The indications 
for HFNC in adults include non-hypercapnic hypoxemic 
respiratory failure requiring relatively high concentrations of 
inspired oxygen. Other applicable settings for HFNC include 
post- extubation support, postoperative respiratory failure, 
intubation support, tracheostomy weaning, and support of 
hypoxemic patients during fiberoptic bronchoscopy.12 
CO poisoning is treated with high levels of supplemental 
oxygen in an effort to displace CO from hemoglobin, other 
heme-containing molecules, and other sites of CO binding.13,14 
This is typically realized clinically by the decrease in time that 
it takes to eliminate CO from hemoglobin in the peripheral 
circulation. At baseline CO is eliminated with a half-life of 
approximately 300 minutes.15 This can be reduced by oxygen 
administration via NRB to between 37-120 minutes.16 Given 
the proposed mechanism of elimination, it stands to reason 
that HFNC could be of similar or greater efficacy as it allows 
for higher oxygen flow rates than NRB.  
There are several theoretical advantages to the use 
of HFNC in treating CO poisoning. HFNC can produce a 
higher partial pressure of oxygen than NRB when applied to 
patients who are tachypneic, potentially resulting in increased 
rate of elimination of CO relative to NRB. This is due to 
the phenomenon of mixing of ambient air into inspired air 
when the volume of air inspired exceeds the flow rate of 
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oxygen delivered by a mask, typically 15 LPM. Given that 
HFNC can provide flow rates exceeding 60 LPM, the extent 
to which ambient air is mixed with supplemental oxygen 
is low; consequently, pO
2
 may be higher. HFNC is better 
tolerated than NRB due to improved comfort and warming 
and humidification of inspired gas, which may allow for better 
compliance with non-invasive oxygen therapy, particularly 
when administering to patients who may be agitated. Lastly, 
should vomiting occur, patients may be less likely to aspirate 
using HFNC as opposed to the NRB.  
Previously, Tomruk et al. reported the use of HFNC 
routinely in a single academic medical center with an increase 
in the decline of absolute COHb levels in one hour compared 
to historical controls that received standard treatment with 
NRB. Mean levels of COHb were 22% in the HFNC group 
and 18.6% in the NRB group prior to treatment.5 Ozturan 
et al. reported a mean half-life of 36.8 minutes calculated 
from 33 patients enrolled with elevated COHb levels (mean 
22.5% COHb prior to treatment) treated with HFNC.4 Neither 
study included any clinical outcome as endpoints. Our patient 
showed a decrease in COHb levels comparable to those 
described for NRB, indicating that HFNC delivered oxygen 
in a manner of comparable efficacy. Further, we were able 
to achieve a high pO
2
 with HFNC. Consequently, we would 
anticipate increased elimination of CO based on the pO
2
 
achieved using HFNC. 
While we did not have adequate data to calculate a 
half-life, our estimate based on the rate of decline of COHb 
between the first and second ABG suggests a half-life of 
approximately 81 minutes, and an estimate between the first 
and third COHb level suggests a half life of 92 minutes.17 
These are consistent with reported half-lives using NRB and 
are exceeded more than four fold by the half-life generally 
reported with ambient air.16,18 The estimated half-life for our 
patient, however, was substantially less than that reported in 
prior studies using HFNC, suggesting that previous reports 
of half-life may not mirror effects in a uncontrolled clinical 
setting. Further, kinetics of elimination may vary as the initial 
COHb level in our patient was approximately 25% higher than 
the mean levels reported in the previous studies. Lastly, our 
patient reported a marked improvement in clinical symptoms 
following HFNC. Neither of the prior reports noted any 
clinical outcome. This is significant as early and late clinical 
findings may not correlate with COHb levels.19 
There are several limitations to the data. First, we did not 
measure clearance directly and thus cannot state unequivocally 
that our half-life estimates are correct. However, given the 
substantial difference between our estimate of half-life and the 
half-life expected on room air, as well as the directly measured 
increase in arterial pO
2
, we feel confident that HFNC had a 
therapeutic effect. Another issue may be that we measured 
an artificially high initial level of COHb as there is an initial 
distribution phase of CO. We think this is unlikely as the 
time lapse between removal from the exposure and obtaining 
blood gas was greater than 30 minutes. Given that the initial 
rate of distribution is rapid we think that our initial COHb 
level likely represents a steady state level.19,20 Also, while our 
patient’s nausea resolved, we have no information regarding 
any long-term clinical issues or whether HFNC administration 
may have any effect on these given the limitations of COHb 
levels in predicting clinical outcome. Further, we cannot say 
this approach would have better outcome that use in NRB 
and antiemetics. Lastly, our patient was a chronic tobacco 
smoker, affecting his baseline levels of COHb and possibly his 
tolerance for elevated COHb levels.
CONCLUSION
In a patient with a CO poisoning, as evidenced by symptoms 
and COHb level, use of HFNC resulted in an apparent increase 
in the rate of elimination of COHb similar to that seen with 
administration of oxygen via NRB. HFNC was well tolerated and 
may be a good option for treatment of CO poisoning.  
Documented patient informed consent and/or Institutional Review 
Board approval has been obtained and filed for publication of this 
case report.
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